查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607980

血紅蛋白疾病市場：按適應症、治療、診斷和最終用戶分類 - 全球預測 2025-2030

Hemoglobinopathies Market by Indication (Sickle Cell Disease, Thalassemia), Treatment (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy), Diagnosis, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年血紅素病市場價值為26.3億美元，預計到2024年將達到27.9億美元，複合年成長率為33.02%，到2030年將達到194.6億美元。

鐮狀細胞疾病和地中海貧血等血紅蛋白疾病是影響血紅蛋白（紅血球中的一種蛋白質）的遺傳性疾病。血紅蛋白病市場範圍包括診斷、治療和支持護理，為患者、醫療保健提供者和研究人員提供服務。與血紅蛋白疾病相關的高發病率和死亡率強調了解決這些疾病的必要性，需要早期診斷、有效管理和定期監測。治療範圍從基因檢測和輸血通訊協定到創新的基因和幹細胞治療。最終用途範圍主要包括醫院、專科診所和專門研究遺傳疾病的研究機構。

主要市場統計
基準年[2023] 26.3億美元
預測年份 [2024] 27.9億美元
預測年份 [2030] 194.6億美元
複合年成長率（%） 33.02%

目前，市場成長的推動因素包括基因研究的進步、患者和醫療保健專業人員意識的提高以及新療法的不斷擴大。值得注意的機會在於開發具有成本效益的基因測試和先進的治療解決方案，例如基於 CRISPR 的基因編輯和小分子藥物。公司還應該探索個人化醫療方法和夥伴關係，旨在改善患者治療結果並降低醫療成本。然而，成長面臨著高昂的治療成本、低收入地區獲得醫療保健的機會有限以及遺傳和臨床研究的複雜性等挑戰。監管障礙和大規模臨床試驗的需要也減緩了新治療方法的開發。

為了克服這些挑戰，公司應該專注於基因治療和照護現場的創新。與生技公司和學術機構建立有效的夥伴關係可以提供合作研究機會並提高研發能力。還可以擴大患者支持計劃和提高認知舉措，以改善有關血紅蛋白病的教育。由於市場是動態的，並且擴大轉向個人化醫療和精準醫療解決方案，市場參與者必須適應這些趨勢並投資於突破性研究，以獲得並保持競爭優勢至關重要。

市場動態：針對快速發展的血紅蛋白病市場揭示的關鍵市場洞察

血紅蛋白病市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 常見罕見血液相關疾病的盛行率不斷上升
    • 尋求血紅蛋白疾病治療的患者數量增加
    • 新型血紅蛋白病治療藥物的監管核准增加
  • 市場限制因素
    • 與血紅蛋白病治療相關的高成本
  • 市場機會
    • 治療血紅蛋白疾病的持續研究和開發活動
    • 治療血紅蛋白疾病的新治療方法和診斷方法的可用性
  • 市場挑戰
    • 對血紅素病治療缺乏認知

波特的五力：駕馭血紅素病市場的策略工具

波特的五力架構是了解血紅素病市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解血紅素病市場的外部影響

外部宏觀環境因素在塑造血紅蛋白病市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解血紅素病市場的競爭狀況

血紅蛋白病市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣血紅素病市場供應商的績效評估

FPNV 定位矩陣是評估血紅素病市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製血紅蛋白病市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對血紅蛋白病市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 常見罕見血液相關疾病的盛行率增加
      • 尋求血紅蛋白疾病治療的患者數量增加
      • 新治療方法的監管核准增加
    • 抑制因素
      • 與血紅蛋白病治療相關的高成本
    • 機會
      • 正在進行的治療血紅蛋白病的研究和開發活動
      • 治療血紅蛋白疾病的新藥物療法和診斷方法的可用性
    • 任務
      • 對血紅素病治療方法缺乏認知
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 血紅素病市場（依適應症）

  • 鐮狀細胞性貧血症
  • 地中海型貧血
    • α地中海貧血
    • BETA地中海型貧血

第7章 依治療分類的血紅素疾病市場

  • 輸血
  • 骨髓和幹細胞移植
  • 化療
  • 治療療法
  • 基因治療
  • 羥基尿素
  • 鐵螯合療法

第8章依診斷分類的血紅素疾病市場

  • 基因檢測
  • 血紅素等電聚焦 (Hb IEF)
  • 血紅素溶解度測試
  • 高效液相層析測定血紅素
  • 血紅素電泳 (Hb ELP)
  • 定期測量紅血球計數 (RBC)

第 9 章 血紅素病市場：按最終用戶

  • 診所
  • 診斷實驗室
  • 醫院

第10章北美和南美的血紅素病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太血紅素病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲/中東/非洲血紅素病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alnylam Pharmaceuticals, Inc.
  • Bio-Rad Laboratories Inc.
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol Myers Squibb
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Emmaus Life Sciences Inc.
  • Gamida Cell Ltd.
  • Genetix Biotech Asia Pvt. Ltd
  • Laboratory Corporation
  • Medunik USA Inc.
  • Merck & Co. Inc.
  • Nexcelom Bioscience LLC
  • Novartis AG
  • PerkinElmer Inc.
  • Pfizer, Inc.
  • Prolong Pharmaceuticals, LLC
  • Regenacy Pharmaceuticals, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sebia
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd
  • Sysmex Corporation
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-C002B1C994F1

The Hemoglobinopathies Market was valued at USD 2.63 billion in 2023, expected to reach USD 2.79 billion in 2024, and is projected to grow at a CAGR of 33.02%, to USD 19.46 billion by 2030.

Hemoglobinopathies, such as sickle cell disease and thalassemia, are genetic disorders affecting hemoglobin, the protein in red blood cells. The scope of the market for hemoglobinopathies encompasses diagnostics, therapeutics, and supportive care, serving patients, healthcare providers, and researchers. The necessity of addressing hemoglobinopathies is underscored by the considerable morbidity and mortality rates associated with these conditions, necessitating early diagnosis, effective management, and periodic monitoring. Applications range from genetic testing and blood transfusion protocols to innovative gene therapies and stem cell treatments. The end-use scope primarily involves hospitals, specialty clinics, and research institutes focused on genetic disorders.

KEY MARKET STATISTICS
Base Year [2023] USD 2.63 billion
Estimated Year [2024] USD 2.79 billion
Forecast Year [2030] USD 19.46 billion
CAGR (%) 33.02%

Currently, market growth is being fueled by advances in genetic research, rising awareness among patients and healthcare professionals, and the expanding pipeline of novel therapies. Notable opportunities lie in developing cost-effective genetic tests and advanced therapeutic solutions such as CRISPR-based gene editing and small molecule drugs. Companies should also explore personalized medicine approaches and partnerships aimed at improving patient outcomes and reducing healthcare costs. However, growth is challenged by high treatment costs, limited access to healthcare in low-income regions, and the complexities involved in genetic and clinical research. Regulatory hurdles and the need for extensive clinical trials can also slow the development of new treatments.

To overcome these challenges, companies should focus on innovations in gene therapy and point-of-care diagnostics. Developing effective partnerships with biotechnological firms and academic institutions can provide collaborative research opportunities and enhance R&D capabilities. There is also scope for expanding patient support programs and awareness initiatives to improve education around hemoglobinopathies. The market is dynamic, with a shift towards personalized and precision medicine solutions, making it imperative for market players to adapt and invest in groundbreaking research that aligns with these trends to capture and sustain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemoglobinopathies Market

The Hemoglobinopathies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of common rare blood-related diseases
    • Rising numbers of patients seeking hemoglobinopathies treatments
    • Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
  • Market Restraints
    • High cost associated with hemoglobinopathies treatment
  • Market Opportunities
    • Ongoing R&D activities for the hemoglobinopathies treatment
    • Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
  • Market Challenges
    • Lack of awareness about hemoglobinopathies therapies

Porter's Five Forces: A Strategic Tool for Navigating the Hemoglobinopathies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemoglobinopathies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemoglobinopathies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemoglobinopathies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemoglobinopathies Market

A detailed market share analysis in the Hemoglobinopathies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemoglobinopathies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemoglobinopathies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemoglobinopathies Market

A strategic analysis of the Hemoglobinopathies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemoglobinopathies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Bio-Rad Laboratories Inc., Biogen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, CRISPR Therapeutics AG, Danaher Corporation, Emmaus Life Sciences Inc., Gamida Cell Ltd., Genetix Biotech Asia Pvt. Ltd, Laboratory Corporation, Medunik USA Inc., Merck & Co. Inc., Nexcelom Bioscience LLC, Novartis AG, PerkinElmer Inc., Pfizer, Inc., Prolong Pharmaceuticals, LLC, Regenacy Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sebia, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Sysmex Corporation, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Hemoglobinopathies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Sickle Cell Disease and Thalassemia. The Thalassemia is further studied across Alpha Thalassemia and Beta thalassemia.
  • Based on Treatment, market is studied across Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy, Curative Therapy, Gene Therapy, Hydroxyurea, and Iron Chelation Therapy.
  • Based on Diagnosis, market is studied across Genetic Testing, Haemoglobin Isoelectric Focusing (Hb IEF), Haemoglobin Solubility Test, Hemoglobin by High Performance Liquid Chromatography, Hemoglobin electrophoresis (Hb ELP), and Routine Red Blood Cell (RBC) Count.
  • Based on End-User, market is studied across Clinics, Diagnostic Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of common rare blood-related diseases
      • 5.1.1.2. Rising numbers of patients seeking hemoglobinopathies treatments
      • 5.1.1.3. Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with hemoglobinopathies treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for the hemoglobinopathies treatment
      • 5.1.3.2. Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness about hemoglobinopathies therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemoglobinopathies Market, by Indication

  • 6.1. Introduction
  • 6.2. Sickle Cell Disease
  • 6.3. Thalassemia
    • 6.3.1. Alpha Thalassemia
    • 6.3.2. Beta thalassemia

7. Hemoglobinopathies Market, by Treatment

  • 7.1. Introduction
  • 7.2. Blood Transfusion
  • 7.3. Bone Marrow & Stem Cell Transplant
  • 7.4. Chemotherapy
  • 7.5. Curative Therapy
  • 7.6. Gene Therapy
  • 7.7. Hydroxyurea
  • 7.8. Iron Chelation Therapy

8. Hemoglobinopathies Market, by Diagnosis

  • 8.1. Introduction
  • 8.2. Genetic Testing
  • 8.3. Haemoglobin Isoelectric Focusing (Hb IEF)
  • 8.4. Haemoglobin Solubility Test
  • 8.5. Hemoglobin by High Performance Liquid Chromatography
  • 8.6. Hemoglobin electrophoresis (Hb ELP)
  • 8.7. Routine Red Blood Cell (RBC) Count

9. Hemoglobinopathies Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals

10. Americas Hemoglobinopathies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hemoglobinopathies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hemoglobinopathies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Bio-Rad Laboratories Inc.
  • 4. Biogen Inc.
  • 5. Bluebird Bio, Inc.
  • 6. Bristol Myers Squibb
  • 7. CRISPR Therapeutics AG
  • 8. Danaher Corporation
  • 9. Emmaus Life Sciences Inc.
  • 10. Gamida Cell Ltd.
  • 11. Genetix Biotech Asia Pvt. Ltd
  • 12. Laboratory Corporation
  • 13. Medunik USA Inc.
  • 14. Merck & Co. Inc.
  • 15. Nexcelom Bioscience LLC
  • 16. Novartis AG
  • 17. PerkinElmer Inc.
  • 18. Pfizer, Inc.
  • 19. Prolong Pharmaceuticals, LLC
  • 20. Regenacy Pharmaceuticals, Inc.
  • 21. Sangamo Therapeutics, Inc.
  • 22. Sanofi S.A.
  • 23. Sebia
  • 24. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
  • 25. Sysmex Corporation
  • 26. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. HEMOGLOBINOPATHIES MARKET RESEARCH PROCESS
  • FIGURE 2. HEMOGLOBINOPATHIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMOGLOBINOPATHIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMOGLOBINOPATHIES MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BONE MARROW & STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CURATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN ISOELECTRIC FOCUSING (HB IEF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN SOLUBILITY TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS (HB ELP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY ROUTINE RED BLOOD CELL (RBC) COUNT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023